MPT: Praluent Delivers Modest CV Event Prevention in ODYSSEY

ACC Conference Reporter

ACC.18 | ORLANDO, FL — Alirocumab (Praluent) reduced major cardiovascular event risks in patients with a recent acute coronary syndrome and elevated cholesterol in the ODYSSEY Outcomes trial, including a win in perhaps the most important outcome: mortality. Read More >>>

Keywords: ACC18, ACC Annual Scientific Session

< Back to Listings